Stocktoria
ACADIA PHARMACEUTICALS INC ACAD
ACADIA PHARMACEUTICALS INC (ACAD) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $1.1B at a 36.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-30 | B of A Securities | Buy (main) |
| 2026-06-29 | Citigroup | Buy (main) |
| 2026-06-29 | Canaccord Genuity | Buy (main) |
| 2026-05-08 | Citigroup | Buy (main) |
| 2026-05-07 | Canaccord Genuity | Buy (main) |
| 2026-03-25 | B of A Securities | Buy (up) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.502 |
| Retained earnings / assets | -1.159 |
| EBIT / assets | 0.067 |
| Equity / liabilities | 3.644 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ACAD | ACADIA PHARMACEUTICALS INC | 4/9 | 3.79 | 11.1 | +11.9% |
| PBH | Prestige Consumer Healthcare Inc. | 5/9 | 4.04 | 12.3 | -4.3% |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | 3/9 | -1.18 | — | +432.1% |
| IONS | IONIS PHARMACEUTICALS INC | 3/9 | 1.12 | — | +33.8% |
| NSRX | Nasus Pharma Ltd | 3/9 | -13.82 | — | — |
| INDV | Indivior Pharmaceuticals, Inc. | 4/9 | -0.7 | 24.3 | +4.3% |
| ANIP | ANI PHARMACEUTICALS INC | 6/9 | 3.26 | 24.5 | +43.8% |
About ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
FAQ
Is ACAD financially healthy?
ACADIA PHARMACEUTICALS INC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ACAD pay a dividend?
No, ACADIA PHARMACEUTICALS INC does not currently pay a dividend.
How profitable is ACAD?
In FY2025, ACADIA PHARMACEUTICALS INC had a net margin of 36.5% and a return on equity of 31.9%.
What is ACAD's P/E ratio?
ACADIA PHARMACEUTICALS INC's trailing price-to-earnings (P/E) ratio is about 11.1×, based on its latest annual earnings.
What is the analyst price target for ACAD?
The average Wall-Street price target for ACADIA PHARMACEUTICALS INC is $32.30, about 9.7% above the recent price, from 20 analysts (consensus: buy).
Is ACAD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ACADIA PHARMACEUTICALS INC: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone, a P/E of about 11.1×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.